Piper Sandler raised the firm’s price target on Idexx Laboratories (IDXX) to $510 from $435 and keeps a Neutral rating on the shares. The firm cites updated estimates and moving forward of its estimate year to 2026 from 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $535 from $475 at BofA
- Idexx Laboratories price target raised to $520 from $481 at Barclays
- Idexx Laboratories: Strong Performance and Promising Future Justify Buy Rating
- IDEXX Laboratories Reports Strong 2024 Financial Results
- IDEXX Labs Earnings Call Highlights Growth and Innovation